Aethlon Medical (AEMD) EBIAT (2016 - 2025)
Aethlon Medical (AEMD) has disclosed EBIAT for 15 consecutive years, with -$6.3 million as the latest value for Q1 2025.
- For the quarter ending Q1 2025, EBIAT fell 157.89% year-over-year to -$6.3 million, compared with a TTM value of -$13.4 million through Mar 2025, down 9.66%, and an annual FY2025 reading of -$13.4 million, down 9.66% over the prior year.
- EBIAT was -$6.3 million for Q1 2025 at Aethlon Medical, down from -$1.8 million in the prior quarter.
- Across five years, EBIAT topped out at -$1.8 million in Q4 2024 and bottomed at -$6.3 million in Q1 2025.
- Average EBIAT over 5 years is -$3.0 million, with a median of -$2.8 million recorded in 2024.
- The sharpest move saw EBIAT skyrocketed 49.37% in 2024, then plummeted 157.89% in 2025.
- Year by year, EBIAT stood at -$2.5 million in 2021, then fell by 12.73% to -$2.8 million in 2022, then fell by 21.63% to -$3.5 million in 2023, then soared by 49.37% to -$1.8 million in 2024, then tumbled by 256.45% to -$6.3 million in 2025.
- Business Quant data shows EBIAT for AEMD at -$6.3 million in Q1 2025, -$1.8 million in Q4 2024, and -$2.8 million in Q3 2024.